Drug Profile
MEDI 9314
Alternative Names: MEDI-9314Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca; MedImmune
- Class Antibodies; Immunotherapies
- Mechanism of Action Interleukin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 25 May 2018 Discontinued - Phase-I for Atopic dermatitis (In volunteers) in United Kingdom, USA (Parenteral) (AstraZeneca pipeline, May 2018)
- 12 Jun 2017 MedImmune completes a phase I trial (In volunteers) for Atopic dermatitis in USA and United Kingdom (Parenteral) (NCT02669667)
- 16 Feb 2016 Preclinical trials in Undefined indication in USA (Parenteral)